Skip to main content

Table 2 Summary of preclinical PK parameters of imatinib (mean) after a single intravenous or oral dose in preclinical species. Data, mean values

From: Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents

PK parameter C57BL/6 mice Prairie dogs
IV Dose (mg/kg) 10 10
No. of animals 3a 5
T1/2 (h) 0.88 2.8 ± 1
MRT (h) 0.77 2.02 ± 0.24
CL (ml/hr./kg) 2212 821 ± 179
Vss (ml/kg) 1697 1666 ± 464
AUC0-inf (ng.hr./ml) 4522 12,558 ± 2189
Oral Dose (mg/kg) 10 30
No. of animals 3a 4
Tmax (h) 1 3 ± 1.15
Cmax (ng/ml) 1468 1677 ± 834
Apparent T1/2 (h) 0.84 2.2 ± 0.6
AUC0-inf (ng.hr./ml) 4852 8092 ± 3012
Bioavailability (%) 107 22
  1. aper time point